ATE234092T1 - 2-alkylpyrrolidine - Google Patents

2-alkylpyrrolidine

Info

Publication number
ATE234092T1
ATE234092T1 AT96928360T AT96928360T ATE234092T1 AT E234092 T1 ATE234092 T1 AT E234092T1 AT 96928360 T AT96928360 T AT 96928360T AT 96928360 T AT96928360 T AT 96928360T AT E234092 T1 ATE234092 T1 AT E234092T1
Authority
AT
Austria
Prior art keywords
alkylpyrrolidine
methylpyrrolidines
hydroxymethylpyrrolidine
dihydroxy
diabetes
Prior art date
Application number
AT96928360T
Other languages
English (en)
Inventor
Karsten Lundgren
Palle Jakobsen
Marit Kristiansen
Leif Norskov-Lauritsen
Lars Narum
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE234092T1 publication Critical patent/ATE234092T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
AT96928360T 1995-09-08 1996-09-06 2-alkylpyrrolidine ATE234092T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK99295 1995-09-08
PCT/DK1996/000373 WO1997009040A1 (en) 1995-09-08 1996-09-06 2-alkylpyrrolidines

Publications (1)

Publication Number Publication Date
ATE234092T1 true ATE234092T1 (de) 2003-03-15

Family

ID=8099807

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928360T ATE234092T1 (de) 1995-09-08 1996-09-06 2-alkylpyrrolidine

Country Status (12)

Country Link
US (2) US5854272A (de)
EP (3) EP0884050A1 (de)
JP (2) JP3043430B2 (de)
CN (1) CN1202105A (de)
AT (1) ATE234092T1 (de)
AU (1) AU724003B2 (de)
CZ (1) CZ120398A3 (de)
DE (1) DE69626660T2 (de)
HU (1) HUP9901132A2 (de)
IL (1) IL124109A (de)
NO (1) NO982055D0 (de)
WO (1) WO1997009040A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ120398A3 (cs) * 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty
US5952363A (en) * 1997-03-04 1999-09-14 Novo Nordisk A/S Pyrrolidine compounds useful in the treatment of diabetes
WO1998040353A1 (en) * 1997-03-07 1998-09-17 Novo Nordisk A/S Novel heterocyclic compounds
JP2002536410A (ja) * 1999-02-12 2002-10-29 ノボ ノルディスク アクティーゼルスカブ 肥満の治療又は予防もしくは食欲の調節を目的とした薬学的組成物の製造におけるピロリジン誘導体の使用
ATE302755T1 (de) * 1999-03-15 2005-09-15 Novo Nordisk As Salz des (2r,3r,4r)3,4-dihydroxy-2- hydroxymethylpyrrolidins
EP1163217B1 (de) * 1999-03-15 2005-09-21 Novo Nordisk A/S Salz des (2r,3r,4r)-3,4-dihydroxy-2-hydroxmethylpyrrolidins
US6316489B1 (en) * 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
DE60037113T2 (de) * 1999-05-24 2008-09-18 Abaron Biosciences, Inc., Del Mar Glycosyltransferase inhibitoren
US6043091A (en) * 1999-07-19 2000-03-28 Isis Pharmaceuticals Inc. Antisense modulation of liver glycogen phosphorylase expression
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6414163B1 (en) * 2000-08-02 2002-07-02 Board Of Trustees Of Michigan State University Process and intermediate compounds for the preparation of pyrrolidines
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
EP1558245A2 (de) * 2002-10-28 2005-08-03 Novo Nordisk A/S Verwendung vonglycogen-phosphorylase-hemmern zur behandlung von herz-kreislauf-erkrankungen
US6960610B2 (en) 2002-10-28 2005-11-01 Novo Nordick, A/S Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2004101505A1 (en) 2003-05-14 2004-11-25 Novo Nordisk A/S Novel compounds for treatment of obesity
JP4486792B2 (ja) * 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
EP1670815A2 (de) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortinrezeptoragonisten
EP2298337B1 (de) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
US20080113944A1 (en) 2004-05-04 2008-05-15 Novo Nordisk A/S Novel Indole Derivatives
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
US20090298745A1 (en) * 2004-12-02 2009-12-03 Gerard Hugh Thomas Treatment of Diabetes with Glycogen Phosphorylase Inhibitors
EP1824835A1 (de) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatische glucokinaseaktivatoren
KR100696187B1 (ko) 2005-05-03 2007-03-20 (주)리드젠 2-(2-아미노에틸)-1-메틸피롤리딘의 제조방법
EP1904467B1 (de) 2005-07-14 2013-05-01 Novo Nordisk A/S Harnstoff-Glucokinase-Aktivatoren
ATE523497T1 (de) 2006-11-15 2011-09-15 High Point Pharmaceuticals Llc Neue 2-(2-hydroxyphenyl)benzimidazole, die sich für die behandlung von obesitas und diabetes eignen
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
WO2010049678A2 (en) * 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
WO2011058975A1 (ja) * 2009-11-11 2011-05-19 国立大学法人富山大学 食後過血糖改善剤、およびピロリジン型イミノ糖またはその塩
EP2539364A1 (de) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptide zur behandlung von adipositas
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2552951A1 (de) 2010-03-26 2013-02-06 Novo Nordisk A/S Neue glocagonanaloga
DK2655388T3 (en) 2010-12-23 2016-09-19 Alectos Therapeutics Inc Selective glykosidaseinhibitorer and uses thereof
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
WO2012129651A1 (en) 2011-03-31 2012-10-04 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
WO2014032185A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014032188A1 (en) 2012-08-31 2014-03-06 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
WO2014067003A1 (en) 2012-10-31 2014-05-08 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2986313B1 (de) 2013-04-18 2019-06-12 Novo Nordisk A/S Stabile, zeitverzögerte coagonisten des glucagon/glp-1-rezeptors
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106349141B (zh) * 2016-08-30 2020-10-27 中国科学院化学研究所 多羟基吡咯烷类化合物及其制备方法和应用
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
WO2025252661A1 (en) 2024-06-03 2025-12-11 Immunic Ag Reducing body weight and/or induction of satiety by triazolo compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1602744A (de) 1968-02-16 1971-01-18
JPS5346967A (en) 1976-10-08 1978-04-27 Kyowa Hakko Kogyo Co Ltd R-2-(beta-halogenoethyl)-1-methyl-pyrrolidine
JPS6058749B2 (ja) 1978-02-09 1985-12-21 日清製粉株式会社 光学活性ｎ‐メチル‐２‐ピロリジンエタノ−ルの製造法
JPS61118360A (ja) 1984-11-13 1986-06-05 Mitsubishi Chem Ind Ltd ピロリジン誘導体またはその塩
US4999360A (en) * 1987-12-21 1991-03-12 Monsanto Company Method of inhibiting virus
US4876268A (en) * 1988-11-03 1989-10-24 G. D. Searle & Co. Antiviral compounds and use thereof
ES2086323T3 (es) * 1988-11-03 1996-07-01 Searle & Co Derivados del didesoxi-arabinitol como compuestos antiviricos.
US4973602A (en) * 1988-11-03 1990-11-27 G. D. Searle & Co. Antiviral compounds and a method of use thereas
US4894388A (en) 1988-12-22 1990-01-16 Monsanto Company Glycosidase inhibitors and use thereof
EP0389723A1 (de) * 1989-03-29 1990-10-03 Merrell Dow Pharmaceuticals Inc. Alpha-glukosidase-Inhibitoren
FR2648486B1 (fr) * 1989-06-16 1991-08-30 Gerland Sa Composition pour le traitement antifeutrant de la laine
EP0422307A1 (de) * 1989-10-10 1991-04-17 Merrell Dow Pharmaceuticals Inc. Alpha-glukosidase-Schutzmittel
US5013842A (en) * 1990-01-22 1991-05-07 Monsanto Company Synthesis of chiral pyrrolidine and piperidine glycosidase inhibitors
US5290948A (en) * 1990-09-17 1994-03-01 Mcneilab, Inc. Process for producing polyhydroxylated piperidines and pyrrolidines and compounds thereof
US5401645A (en) 1992-03-16 1995-03-28 Monsanto Company Process for producing n-substituted polyhydroxy nitrogen-containing heterocycles utilizing acetobacteraceae and corynebacterium
JPH0625157A (ja) 1992-07-13 1994-02-01 Taisho Pharmaceut Co Ltd ポリヒドロキシピロリジン誘導体類およびその製造方法
CZ120398A3 (cs) * 1995-09-08 1998-12-16 Novo Nordisk A/S Použití 2-alkylpyrrolidinových derivátů pro přípravu léčiva pro léčbu diabetu, 2-alkylpyrrolidiné deriváty

Also Published As

Publication number Publication date
DE69626660T2 (de) 2003-08-21
US5854272A (en) 1998-12-29
DE69626660D1 (en) 2003-04-17
JP2000095686A (ja) 2000-04-04
JP3043430B2 (ja) 2000-05-22
EP1040827A2 (de) 2000-10-04
EP0858335B1 (de) 2003-03-12
AU6785996A (en) 1997-03-27
WO1997009040A1 (en) 1997-03-13
CN1202105A (zh) 1998-12-16
EP0858335A1 (de) 1998-08-19
NO982055L (no) 1998-05-06
HUP9901132A2 (hu) 1999-07-28
NO982055D0 (no) 1998-05-06
CZ120398A3 (cs) 1998-12-16
IL124109A (en) 2001-10-31
US6451836B1 (en) 2002-09-17
JPH11503762A (ja) 1999-03-30
EP1040827A3 (de) 2000-10-11
IL124109A0 (en) 1998-12-06
EP0884050A1 (de) 1998-12-16
AU724003B2 (en) 2000-09-07

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
EA199800857A1 (ru) Композиция для снятия боли и способ снятия боли
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
ES2149268T3 (es) Procedimiento de estabilizacion de bebidas.
TR200100922T2 (tr) Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
BG102644A (bg) Подобрени концентрирани инжекционни и инфузионниразтвори за интравазално прилагане
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
MXPA02004666A (es) Gelatinas recombinantes.
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
DE59807248D1 (de) Implantatkörper
FI923680L (fi) Foerfarande foer framstaellning av (2r,3r) cis-b-fenylglysidinsyra
SE9802937D0 (sv) Novel compounds
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO963526D0 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)-etylÅ-2,2-difenylacetamid
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
ES2195655T3 (es) Procedimiento para tratar fiebre hemorragica virica con proteina c.
MA24485A1 (fr) Atropisomeres de 3-heteroaryl-4(3h)-quinazo linones .
ID16192A (id) Proses pembuatan asam-asam .alpha., beta-karboksilat organik tak jenuh
ES2172682T3 (es) Preparaciones desodorantes con contenido en quitosano, clorohidrato de aluminio e inhibidores de esterasa.
DK0929299T3 (da) Substituerede 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyclohepta-(b)benzofuraner
NO20005548D0 (no) Mykobakterieinhibitorer
EA199900579A1 (ru) Применение ингибиторов комт для производства лекарственного средства для профилактики сосудистых дисфункций при диабете
ES2175842T3 (es) Antagonistas de kv2.1.
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung
IT1290910B1 (it) 2-amminotetralina otticamente attiva, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono, attive

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties